Stuka Paul 4

What Happened

• Paul Stuka, a director of InspireMD (NSPR), made open-market purchases totaling 75,626 shares of common stock: 65,626 shares on May 8 at a weighted average price of $1.16 (≈ $76,126) and 10,000 shares on May 11 at a weighted average price of $1.19 (≈ $11,900). Total consideration for the purchases was about $88,026. These were purchases (insider buys), which investors often view as a more informative signal than routine sales.

Key Details

• Transaction dates & prices:
  • 2026-05-08 — 65,626 shares at a weighted avg price reported as $1.16 (individual trades ranged $1.15–$1.16). (Footnote F1)
  • 2026-05-11 — 10,000 shares at a weighted avg price reported as $1.19 (individual trades ranged $1.17–$1.20). (Footnote F4)
• Shares owned after the transactions (as reported):
  • Directly beneficially owned: approx. 632,871 shares (557,245 before these purchases + 75,626 purchased).
  • Indirectly beneficially owned through Osiris Investment Partners, L.P.: 423,704 shares (no change reported). (Footnotes F2, F3)
• Other notable footnotes:
  • F2–F5 explain corrections to prior filings and clarify certain shares are held by Osiris; Stuka serves as managing member of Osiris Partners, LLC and disclaims beneficial ownership except to the extent of his pecuniary interest.
  • No 10b5-1 plan, option exercise, gift, or tax-withholding event was reported — these were straight open-market purchases (code P).
• Filing timeliness: The Form 4 was filed May 12, 2026 and covers purchases on May 8 and May 11; this filing is within the SEC’s two-business-day window and is therefore timely.

Context

• These were direct open-market purchases (not option exercises or awards). Purchases by directors can reflect confidence in the company, but they are one data point among many — avoid assuming motive. The footnotes clarify prior reporting corrections and the distinction between shares held directly vs. indirectly through an entity Stuka manages.